Logo image of CRON.CA

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

TSX:CRON - Toronto Stock Exchange - CA22717L1013 - Common Stock - Currency: CAD

2.63  -0.06 (-2.23%)

Fundamental Rating

5

Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 35 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.
CRON had a positive operating cash flow in the past year.
In the past 5 years CRON reported 4 times negative net income.
CRON had negative operating cash flow in 4 of the past 5 years.
CRON.CA Yearly Net Income VS EBIT VS OCF VS FCFCRON.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

The Return On Assets of CRON (4.29%) is better than 88.57% of its industry peers.
CRON has a better Return On Equity (4.64%) than 82.86% of its industry peers.
Industry RankSector Rank
ROA 4.29%
ROE 4.64%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON.CA Yearly ROA, ROE, ROICCRON.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON's Profit Margin of 39.68% is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
CRON has a Gross Margin of 27.65%. This is in the lower half of the industry: CRON underperforms 65.71% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 39.68%
GM 27.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON.CA Yearly Profit, Operating, Gross MarginsCRON.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRON has been increased compared to 1 year ago.
The number of shares outstanding for CRON has been increased compared to 5 years ago.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON.CA Yearly Shares OutstandingCRON.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON.CA Yearly Total Debt VS Total AssetsCRON.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 6.67 indicates that CRON is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.67, CRON belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.67
ROIC/WACCN/A
WACC8.75%
CRON.CA Yearly LT Debt VS Equity VS FCFCRON.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

CRON has a Current Ratio of 27.80. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 27.80, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
CRON has a Quick Ratio of 26.75. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a better Quick ratio (26.75) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 27.8
Quick Ratio 26.75
CRON.CA Yearly Current Assets VS Current LiabilitesCRON.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 285.71% over the past year.
The earnings per share for CRON have been decreasing by -50.78% on average. This is quite bad
Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 33.92%.
CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)33.92%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%27.58%

3.2 Future

Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.14% on average per year.
The Revenue is expected to grow by 1.87% on average over the next years.
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON.CA Yearly Revenue VS EstimatesCRON.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON.CA Yearly EPS VS EstimatesCRON.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.61, which indicates a correct valuation of CRON.
CRON's Price/Earnings ratio is rather cheap when compared to the industry. CRON is cheaper than 85.71% of the companies in the same industry.
CRON is valuated rather cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 23.64, CRON is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 77.14% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (22.13), we can say CRON is valued inline with the index average.
Industry RankSector Rank
PE 14.61
Fwd PE 23.64
CRON.CA Price Earnings VS Forward Price EarningsCRON.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON.CA Per share dataCRON.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as CRON's earnings are expected to decrease with -39.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

TSX:CRON (6/13/2025, 7:00:00 PM)

2.63

-0.06 (-2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners13.13%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner ChangeN/A
Market Cap1.01B
Analysts76
Price Target2.4 (-8.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.6%
Min Revenue beat(2)-14.99%
Max Revenue beat(2)-0.21%
Revenue beat(4)2
Avg Revenue beat(4)-0.3%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)4
Avg Revenue beat(12)-4.65%
Revenue beat(16)7
Avg Revenue beat(16)-2.62%
PT rev (1m)-34.81%
PT rev (3m)-34.1%
EPS NQ rev (1m)100%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-749.62%
Revenue NQ rev (1m)-5.74%
Revenue NQ rev (3m)-11.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 14.61
Fwd PE 23.64
P/S 5.97
P/FCF N/A
P/OCF 39.23
P/B 0.7
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)0.18
EY6.84%
EPS(NY)0.11
Fwd EY4.23%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.07
OCFY2.55%
SpS0.44
BVpS3.77
TBVpS3.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.29%
ROE 4.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 39.68%
GM 27.65%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 253.86%
Cap/Sales 21.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.8
Quick Ratio 26.75
Altman-Z 6.67
F-Score6
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)33.92%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%27.58%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%
EBIT growth 1Y32.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.02%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y92.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.45%
OCF growth 3YN/A
OCF growth 5YN/A